RPLND Indications in Non-Seminomatous Germ Cell Testicular Cancer
For post-chemotherapy nonseminomatous germ cell tumors, resection is mandatory for all residual masses >1 cm in greatest diameter on cross-sectional imaging, performed within 6-8 weeks after completing chemotherapy 1.
Post-Chemotherapy Setting (Primary Indication)
The most critical indication for RPLND in nonseminoma is the post-chemotherapy residual mass. No diagnostic tool or risk calculator can accurately predict the histology of these residual masses, making surgical resection the only definitive approach 1.
Size-Based Algorithm:
- >1 cm residual mass: RPLND is mandatory 1
- <1 cm residual mass: Role is uncertain; close surveillance is an alternative with 6-9% recurrence risk 1
- After salvage chemotherapy or high-dose chemotherapy: Surgery indicated even for masses <1 cm due to higher risk of harboring active disease 1
Timing:
Perform surgery within 6-8 weeks after the last chemotherapy cycle 1.
Clinical Stage IIA Disease
For clinical stage IIA nonseminoma, RPLND represents one of several treatment options alongside chemotherapy (BEP × 3 cycles) or surveillance 1. This is particularly relevant for patients with pathological stage IIA/B after initial treatment, where nerve-sparing RPLND can be followed by selective adjuvant chemotherapy if needed 1.
High-Risk Clinical Stage I Disease
While not explicitly detailed in the most recent guidelines, RPLND has established utility in clinical stage I patients with high-risk features (embryonal carcinoma predominance and/or lymphovascular invasion) who are not candidates for surveillance 2. This approach identifies pathological stage II disease in approximately 42% of cases and allows 72% of patients to avoid chemotherapy when adjuvant treatment is restricted to PN2 disease 2.
Special Circumstances
Growing Teratoma Syndrome:
When markers normalize but masses with features of postpubertal teratoma progress during chemotherapy, early surgical resection should be considered 1.
Low-Level AFP Plateau:
For patients with persistently low AFP after chemotherapy completion, removal of residual masses is advised followed by subsequent AFP monitoring 1.
Multiple Sites of Disease:
Surgery should commence at the site with highest volume of residual disease 1. When both retroperitoneal and lung masses are present, finding fibrosis/necrosis in the retroperitoneum predicts 90% probability of the same histology in lung masses 1.
Technical Considerations
Bilateral nerve-sparing RPLND is the standard approach when resection is indicated 1. Ipsilateral template resection may be considered for residual masses <5 cm diameter with unilateral lymph node metastases on pre- and post-chemotherapy imaging 1.
Laparoscopic/Robotic Approach:
May yield comparable outcomes in selected cases with low-volume residual disease when performed by very experienced surgeons, though long-term data verifying comparability with open surgery are lacking 1. This should only be considered in specialist centers with expertise in both open RPLND and minimally invasive surgery 1.
Critical Pitfalls
- Do not delay surgery beyond 6-8 weeks post-chemotherapy - timing is crucial for optimal outcomes
- Do not rely on imaging or markers alone to determine need for surgery in post-chemotherapy residual masses >1 cm
- Do not perform RPLND outside of referral centers for complex cases, particularly salvage situations or after multiple chemotherapy cycles, as these carry significantly higher complication risks 3
- Preoperatively elevated AFP is an independent predictor of grade III-V complications (OR 3.3) 3